Clinical Trial

TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 1, 2024 (before its estimated January 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Hepatocellular carcinoma (HCC) patients with Vp4 \[main trunk\] portal vein tumor thrombosis (PVTT) face a significantly poor prognosis, and current treatment options provide limited benefits. We aimed to assess the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with immune checkpoint inhibitors (ICIs) plus molecular targeted therapy (MTT) after irradiation stent placement (ISP) as first line treatment for HCC patients with Vp4 PVTT.
Trial Details
NCT Number NCT06669377
Lead Sponsor Zhongda Hospital
Conditions Hepatocellular Carcinoma
Enrollment 444 participants
Start Date 2024-01-01
Primary Completion 2025-01-31 (estimated)
Study Completion 2025-03-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-01